Stuart Kupfer

8.9k citations

82 papers · 5.6k indexed · 4 hit papers · h-index 27

Impact in

Endocrinology, Diabetes and Metabolism top 0.2%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Hormonal Regulation and Hypertension
Cardiology and Cardiovascular Medicine top 0.5%
- Blood Pressure and Hypertension Studies
- Cardiovascular Function and Risk Factors

Papers in ⓘ

Endocrinology, Diabetes and Metabolism 44
- Hormonal Regulation and Hypertension 24
- Diabetes Treatment and Management 20
Cardiology and Cardiovascular Medicine 58
- Blood Pressure and Hypertension Studies 28
- Cardiovascular Function and Risk Factors 16
- Heart Failure Treatment and Management 11
- Cardiomyopathy and Myosin Studies 8
- Atrial Fibrillation Management and Outcomes 5

Co-authors: George L. Bakris (29 shared papers)William B. White (25 shared papers)William C. Cushman (14 shared papers)Faı̈ez Zannad (13 shared papers)Christopher P. Cannon (11 shared papers)Cyrus R. Mehta (9 shared papers)Alfonso T. Perez (5 shared papers)Craig Wilson (9 shared papers)
Journals: Journal of Hypertension (10 papers)Journal of Clinical Hypertension (7 papers)European Heart Journal (7 papers)Journal of the American College of Cardiology (6 papers)Circulation (3 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Stuart Kupfer

71 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial 2015 · 551 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 The Lancet
2013 New England Journal of Medicine
2008 JAMA
2006 Annals of Internal Medicine

Peers

Countries citing papers authored by Stuart Kupfer

Since Specialization

Citations

This map shows the geographic impact of Stuart Kupfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Kupfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Kupfer more than expected).

Fields of papers citing papers by Stuart Kupfer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Kupfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Kupfer. The network helps show where Stuart Kupfer may publish in the future.

Co-authors

The 25 scholars most cited alongside Stuart Kupfer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stuart Kupfer Line = papers co-authored together Stuart Kupfer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes New England Journal of Medicine ·William B. White, Christopher P. Cannon, Simon Heller, Steven E. Nissen, Richard M. Bergenstal, George L. Bakris, Alfonso T. Perez, P. Fleck, Cyrus R. Mehta, Stuart Kupfer, Craig Wilson, William C. Cushman, Faı̈ez Zannad Hit paper breakdown →	2013	1857
2	Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes JAMA ·Steven E. Nissen, Stephen J. Nicholls, Kathy Wolski, Richard W. Nesto, Stuart Kupfer, Alfonso Pérez, Horacio O. Jure, Robert De Larochellière, Cezar Staniloae, Kreton Mavromatis, Jacqueline Saw, Bo Hu, A. Michael Lincoff, E. Murat Tuzcu, for the PERISCOPE Investigators Hit paper breakdown →	2008	664
3	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial The Lancet ·Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman, George L. Bakris, Venu Menon, Alfonso T. Perez, P. Fleck, Cyrus R. Mehta, Stuart Kupfer, Craig Wilson, Hung‐Ming Lam, William B. White Hit paper breakdown →	2015	551
4	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? Annals of Internal Medicine ·Franz H. Messerli, Giuseppe Mancia, C Conti, Ann C. Hewkin, Stuart Kupfer, Annette Champion, R. Kolloch, Athanase Bénétos, Carl J. Pepine Hit paper breakdown →	2006	507
5	Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke Stroke ·Robert Wilcox, Marie‐Germaine Bousser, D. J. Betteridge, Guntram Schernthaner, Valdis Pīrāgs, Stuart Kupfer, John Dormandy	2007	348
6	Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension Hypertension ·William B. White, Michael A. Weber, Domenic Sica, George L. Bakris, Alfonso Pérez, Charlie Cao, Stuart Kupfer	2011	168
7	The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure Journal of Clinical Hypertension ·George L. Bakris, Domenic Sica, Michael A. Weber, William B. White, Andrew W. Roberts, Alfonso Pérez, Charlie Cao, Stuart Kupfer	2011	110
8	Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) American Heart Journal ·Robert Wilcox, Stuart Kupfer, Erland Erdmann	2008	101
9	Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring Journal of Clinical Hypertension ·Domenic Sica, William B. White, Michael A. Weber, George L. Bakris, Alfonso Pérez, Charlie Cao, Alison Handley, Stuart Kupfer	2011	91
10	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients Journal of the American College of Cardiology ·Stephen J. Nicholls, E. Murat Tuzcu, Kathy Wolski, Özgür Bayturan, Andrea Lavoie, Kiyoko Uno, Stuart Kupfer, Alfonso Pérez, Richard W. Nesto, Steven E. Nissen	2011	82
11	Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil The American Journal of Medicine ·George L. Bakris, Domenic Sica, William B. White, William C. Cushman, Michael A. Weber, Alison Handley, Eric Song, Stuart Kupfer	2012	74
12	A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes Pharmacoepidemiology and Drug Safety ·Charles M. Gerrits, Mondira Bhattacharya, Shivaji Manthena, Robert W. Baran, Alfonso García‐Pérez, Stuart Kupfer	2007	67
13	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure JAMA Cardiology ·G. Michael Felker, Scott D. Solomon, Brian Claggett, Rafael Díaz, John J.V. McMurray, Marco Metra, Inder S. Anand, María G. Crespo‐Leiro, Ulf Dahlström, Eva Gonçalvesová, Jonathan G. Howlett, Peter S. Macdonald, Alexander Parkhomenko, János Tomcsányi, Siddique Abbasi, Stephen B. Heitner, Thomas Hucko, Stuart Kupfer, Fady I. Malik, John R. Teerlink	2021	61
14	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]) The American Journal of Cardiology ·Rhonda M. Cooper‐DeHoff, Jerome D. Cohen, George L. Bakris, Franz H. Messerli, Serap Erdine, Ann C. Hewkin, Stuart Kupfer, Carl J. Pepine	2006	59
15	Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension Hypertension ·William C. Cushman, George L. Bakris, William B. White, Michael A. Weber, Domenic Sica, Andrew W. Roberts, Eric Lloyd, Stuart Kupfer	2012	54
16	Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy Diabetes and Vascular Disease Research ·Paulos Berhanu, Mark Kipnes, Mehmood Khan, Alfonso T. Perez, Stuart Kupfer, Robert G. Spanheimer, Seleshi Demissie, P. Fleck	2006	50
17	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial Diabetes Care ·William B. White, Stuart Kupfer, Faı̈ez Zannad, Cyrus R. Mehta, Craig Wilson, Lanyu Lei, George L. Bakris, Steven E. Nissen, William C. Cushman, Simon Heller, Richard M. Bergenstal, P. Fleck, Christopher P. Cannon	2016	48
18	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Circulation ·Matthew A. Cavender, William B. White, Petr Jarolı́m, George L. Bakris, William C. Cushman, Stuart Kupfer, Qi Gao, Cyrus R. Mehta, Faı̈ez Zannad, Christopher P. Cannon, David A. Morrow	2017	46
19	Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril Journal of Human Hypertension ·Gerd Bönner, George L. Bakris, Domenic Sica, Michael A. Weber, William B. White, Alfonso Pérez, Chang Cao, Alison Handley, Stuart Kupfer	2013	41
20	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: T he EXAMINE trial Diabetes Obesity and Metabolism ·Simon Heller, Richard M. Bergenstal, William B. White, Stuart Kupfer, George L. Bakris, William C. Cushman, Cyrus R. Mehta, Steven E. Nissen, Craig Wilson, Faı̈ez Zannad, Yuyin Liu, Noah M. Gourlie, Christopher P. Cannon, (unknown)	2017	41

About Stuart Kupfer

Stuart Kupfer is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Nutrition and Dietetics, Internal Medicine and Geriatrics and Gerontology, having authored 82 papers that have together received 5.6k indexed citations. Recurring topics across this work include Blood Pressure and Hypertension Studies (28 papers), Hormonal Regulation and Hypertension (24 papers), Diabetes Treatment and Management (20 papers), Cardiovascular Function and Risk Factors (16 papers), Heart Failure Treatment and Management (11 papers), Sodium Intake and Health (11 papers), Cardiomyopathy and Myosin Studies (8 papers) and Atrial Fibrillation Management and Outcomes (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.0k citations), Cardiology and Cardiovascular Medicine (2.3k citations), Surgery (1.3k citations), Pharmacology (480 citations) and Molecular Biology (1.6k citations). Stuart Kupfer has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include George L. Bakris, William B. White, William C. Cushman, Faı̈ez Zannad, Christopher P. Cannon, Cyrus R. Mehta, Alfonso T. Perez, Craig Wilson, P. Fleck and Steven E. Nissen. Their work appears in journals such as Journal of Hypertension, Journal of Clinical Hypertension, European Heart Journal, Journal of the American College of Cardiology and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact